Cosentyx® (secukinumab) – New formulation approval
October 6, 2023 - Novartis announced the FDA approval of an intravenous (IV) formulation of Cosentyx (secukinumab), for the treatment of adults with active psoriatic arthritis (PsA), active ankylosing spondylitis (AS), and active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.
Top